A startling new study has raised serious questions for millions managing type 2 diabetes. Researchers found that stopping a popular class of diabetes drugs could nearly double the risk of suffering a heart attack, stroke, or even death.
A 'Doubled Risk' Warning
A recent study
published in The Lancet Regional Health Europe delivered a stark warning for patients with type 2 diabetes. Researchers who analyzed the health records of over 80,000 people in Italy found that those who stopped taking GLP-1 receptor agonist drugs faced a significantly higher risk of serious health problems. Specifically, discontinuing the medication was associated with approximately double the risk of a non-fatal heart attack, non-fatal stroke, or death from any cause compared to those who continued their treatment. The data, collected over two decades, showed that about four out of every 100 people per year who stopped treatment had a major cardiovascular event, compared to just two out of 100 who stayed on the medication.
The Drugs in Focus: GLP-1 Agonists
The medications at the centre of this research are GLP-1 receptor agonists, a class of drugs that have become essential in managing type 2 diabetes and, more recently, for weight loss. These drugs, which include well-known brands like Ozempic, Mounjaro, and Wegovy, work by mimicking a natural hormone that helps regulate blood sugar and reduces appetite. Beyond their primary function of glucose control, these medications have been celebrated for their powerful cardiovascular benefits, actively protecting the heart and blood vessels. This protective effect is a key reason they are prescribed to many with type 2 diabetes, a condition that itself significantly increases the risk of heart disease.
Why Does Stopping Erase the Benefits?
The cardiovascular protection offered by GLP-1 drugs appears to be dependent on continuous use. When the medication is stopped, these benefits can fade surprisingly quickly. Another study from Washington University noted that interrupting treatment for as little as six months was linked to an increased risk. After two years off the medication, the risk of heart attack, stroke, and death was up to 22% higher, essentially wiping out the protection gained while on the drug. While weight regain and rising blood sugar are expected consequences of stopping, researchers noted that these factors alone didn't seem to fully explain the sharp rise in cardiovascular risk, suggesting the drugs have a more direct and immediate protective effect on the heart that is lost upon discontinuation.
A Chronic Treatment for a Chronic Condition
Experts emphasize that type 2 diabetes and obesity are chronic conditions that often require longterm management. The findings from recent studies reinforce the idea that GLP1s should not be viewed as a shortterm fix. Many patients stop taking the drugs for various reasons, including high costs, inconvenient side effects like nausea, or because they have reached their weight loss goals. However, experts caution that stopping the medication without medical guidance can lead to a 'metabolic whiplash', where the body not only regains weight but also loses the crucial, unseen protection against heart disease.
What Should Patients Do?
The key takeaway from this research is not that the drugs are dangerous, but that their benefits are tied to consistent use. It is crucial for anyone taking a GLP1 medication for diabetes not to stop or alter their dosage without first consulting their doctor. If a patient needs to discontinue the drug due to side effects or other issues, their doctor can develop a plan to manage their health and mitigate the risks. This might involve gradually tapering off the medication or transitioning to an alternative treatment to maintain control over blood sugar and cardiovascular health. Open communication with a healthcare provider is the most important step in ensuring longterm health and safety.
